HomeNewsQuality / GMP

Zydus receives EIR from the USFDA for its SEZ 1 manufacturing facility at Pharmez, Ahmedabad

Zydus receives EIR from the USFDA for its SEZ 1 manufacturing facility at Pharmez, Ahmedabad

Zydus Lifesciences Ltd has received the Establishment Inspection Report (EIR) from the USFDA for the inspection conducted at its manufacturing facility located at Pharmez, Ahmedabad from March 20 to 24, 2023. The inspection has been classified as Voluntary Action Indicated (VAI). The EIR report indicates that the inspection is closed.

More news about: quality / gmp | Published by Sudeep Soparkar | July - 06 - 2023 | 448

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members